热门资讯> 正文

Anavex生命科学GAAP每股收益为-0.06美元

2026-07-30 20:14

Anavex Life Sciences Corp.(AVXL) 0

Anavex Life Sciences press release (AVXL): Q2 GAAP EPS of -$0.06.
Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102.6 million as of September 30, 2025. The Company expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid-to-late fiscal 2028.

More on Anavex Life Sciences

Anavex Life Sciences: Waiting On Validation As Blarcamesine Shows Some Promise
Anavex Life Sciences receives Nasdaq delinquency notice
Anavex slips after CEO transition
Seeking Alpha’s Quant Rating on Anavex Life Sciences
Historical earnings data for Anavex Life Sciences

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。